Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000199952 | SCV000249918 | uncertain significance | not provided | 2014-10-13 | criteria provided, single submitter | clinical testing | The V1602M variant has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. The NHLBI Exome Sequencing Project (and the 1000 Genomes Project) reports V1602M was observed in 1/978 alleles from individuals of Southeast Asian background, indicating it may be a rare (benign) variant in this population. The V1602M variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. This substitution occurs at a position that is not conserved across evolution, and M1602 is present in several species. As a result, in silico analysis predicts this variant likely does not alter the protein structure/function. Furthermore, no missense mutations in nearby residues have been reported in association with Ehlers-Danlos syndrome, indicating that this region of the protein may be tolerant of change. Morevoer, the V1602M variant does not affect a Glycine residue in a Gly-X-Y motif in the triple helical region of the COL5A1 gene, where the majority of missense mutations occur (Symoens et al., 2012). Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic mutation or a rare benign variant.This variant was found in TAAD |
| MGZ Medical Genetics Center | RCV002288797 | SCV002581452 | uncertain significance | Ehlers-Danlos syndrome, classic type, 1 | 2022-03-14 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV002288797 | SCV002957190 | likely benign | Ehlers-Danlos syndrome, classic type, 1 | 2022-10-26 | criteria provided, single submitter | clinical testing |